“If GST is applied on medicines and implants used on patients instead of a composite tax rate, then this may result in a huge impact and ho...

NPPA had slashed prices of drug eluting stents & bioresorable vascular scaffolds as it found companies were making nearly 400% profits on t...

The move is expected to preempt any shortages and ensure uninterrupted supply of a variety of high quality primary and revision knee implan...

The company asserted that its decision to withdraw Abbott was based on “low commercial uptake” and this was reflected in the sales figures ...

Abbott’s move also comes while several regulators in different countries have scrutinised this scaffold, used in life saving procedures, ov...

CIC said mere capping of stent prices will not end the exploitation of the patients, govt should consider capping the cost of entire operat...

Doctors and industry executives often claim huge margins are built into the original cost to push particular brands, sometimes unnecessary ...

The Central Drugs Standard Control Organization (CDSCO)'s note posted on its website cited "safety concerns" as the reason.

The development comes in the wake of several studies showing that bioresorbable cardiac stents are not only not superior to existing DES, b...

In a letter to PM Modi, the Alliance of Doctors for Ethical Healthcare (ADEH) said these drugs and implants are also charged "exorbitantly"...

The National Pharmaceutical Pricing Authority (NPPA) has begun scrutiny of such devices, even asking makers to log in every detail about th...

According to data from the drug pricing regulator, hospitals were found earning exorbitant margins on stents—over 650% in some cases.

There is no regulation of hospitals in India, especially in the private sector where a majority of urban Indians seek healthcare.

In a letter to the secretary in the health ministry, the 4,500-member grouping has suggested that stents should be considered under differe...

The National Health Systems Resource Centre has suggested price caps in a report to drug pricing regulator National Pharmaceutical Pricing ...

Now patients are being told that the stent costing Rs 42,000 is better in quality than the one that costs Rs 23,625.

The decision of Johnson&Johnson to stop making its popular drug eluting stent has opened up new opportunities for competitors Abbott & Bost...